EE284 Cost-Effectiveness of Pembrolizumab in Combination With Chemotherapy As First-Line Treatment of Advanced or Metastatic Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma in France
Abstract
Authors
T Aparicio C Mackosso L Cagnan L Bensimon B Tehard M Boussahoua S Zhang T Qu Y Meng E François